nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—lung cancer—vascular cancer	0.887	1	CtDrD
Crizotinib—STK10—renal vein—vascular cancer	0.012	0.257	CbGeAlD
Crizotinib—EPHA2—pulmonary artery—vascular cancer	0.00476	0.102	CbGeAlD
Crizotinib—MET—blood vessel—vascular cancer	0.00264	0.0565	CbGeAlD
Crizotinib—TIE1—blood vessel—vascular cancer	0.00202	0.0432	CbGeAlD
Crizotinib—RIPK2—blood vessel—vascular cancer	0.00166	0.0355	CbGeAlD
Crizotinib—PTK2—blood vessel—vascular cancer	0.00154	0.033	CbGeAlD
Crizotinib—EPHB4—blood vessel—vascular cancer	0.0014	0.03	CbGeAlD
Crizotinib—JAK2—blood vessel—vascular cancer	0.00139	0.0298	CbGeAlD
Crizotinib—EPHA2—blood vessel—vascular cancer	0.00137	0.0294	CbGeAlD
Crizotinib—TEK—blood vessel—vascular cancer	0.00134	0.0287	CbGeAlD
Crizotinib—SRC—blood vessel—vascular cancer	0.00119	0.0255	CbGeAlD
Crizotinib—FER—cardiac atrium—vascular cancer	0.000873	0.0187	CbGeAlD
Crizotinib—TIE1—cardiac atrium—vascular cancer	0.000816	0.0175	CbGeAlD
Crizotinib—TESK1—cardiac atrium—vascular cancer	0.000789	0.0169	CbGeAlD
Crizotinib—MAP3K12—cardiac atrium—vascular cancer	0.000743	0.0159	CbGeAlD
Crizotinib—ACVR1—cardiac atrium—vascular cancer	0.000743	0.0159	CbGeAlD
Crizotinib—STK35—cardiac atrium—vascular cancer	0.000727	0.0156	CbGeAlD
Crizotinib—RIPK2—cardiac atrium—vascular cancer	0.000671	0.0144	CbGeAlD
Crizotinib—EPHA4—cardiac atrium—vascular cancer	0.000648	0.0139	CbGeAlD
Crizotinib—TBK1—cardiac atrium—vascular cancer	0.000623	0.0133	CbGeAlD
Crizotinib—TYK2—cardiac atrium—vascular cancer	0.000619	0.0132	CbGeAlD
Crizotinib—RPS6KB1—cardiac atrium—vascular cancer	0.000599	0.0128	CbGeAlD
Crizotinib—AXL—cardiac atrium—vascular cancer	0.000593	0.0127	CbGeAlD
Crizotinib—SLK—cardiac atrium—vascular cancer	0.000571	0.0122	CbGeAlD
Crizotinib—EPHB4—cardiac atrium—vascular cancer	0.000567	0.0121	CbGeAlD
Crizotinib—JAK2—cardiac atrium—vascular cancer	0.000563	0.0121	CbGeAlD
Crizotinib—EPHA2—cardiac atrium—vascular cancer	0.000556	0.0119	CbGeAlD
Crizotinib—TEK—cardiac atrium—vascular cancer	0.000542	0.0116	CbGeAlD
Crizotinib—MAP3K3—cardiac atrium—vascular cancer	0.000542	0.0116	CbGeAlD
Crizotinib—MAP4K5—cardiac atrium—vascular cancer	0.000542	0.0116	CbGeAlD
Crizotinib—EPHB6—cardiac atrium—vascular cancer	0.000518	0.0111	CbGeAlD
Crizotinib—YES1—cardiac atrium—vascular cancer	0.000501	0.0107	CbGeAlD
Crizotinib—TAOK3—cardiac atrium—vascular cancer	0.000494	0.0106	CbGeAlD
Crizotinib—SRC—cardiac atrium—vascular cancer	0.000482	0.0103	CbGeAlD
Crizotinib—CSF1R—cardiac atrium—vascular cancer	0.000433	0.00926	CbGeAlD
Crizotinib—ABL1—cardiac atrium—vascular cancer	0.000342	0.00732	CbGeAlD
Crizotinib—SRC—Kit receptor signaling pathway—MITF—vascular cancer	0.000337	0.00512	CbGpPWpGaD
Crizotinib—FES—Signaling by SCF-KIT—TSC2—vascular cancer	0.00032	0.00487	CbGpPWpGaD
Crizotinib—RPS6KB1—mTOR signaling pathway—TSC2—vascular cancer	0.000313	0.00476	CbGpPWpGaD
Crizotinib—RPS6KB1—PI3K Cascade—TSC2—vascular cancer	0.000306	0.00465	CbGpPWpGaD
Crizotinib—RPS6KB1—AMPK Signaling—TSC2—vascular cancer	0.000302	0.0046	CbGpPWpGaD
Crizotinib—SRC—FSH signaling pathway—TSC2—vascular cancer	0.000293	0.00446	CbGpPWpGaD
Crizotinib—MAPK7—BDNF signaling pathway—TSC2—vascular cancer	0.000279	0.00424	CbGpPWpGaD
Crizotinib—ABCB1—blood vessel—vascular cancer	0.000263	0.00563	CbGeAlD
Crizotinib—IGF1R—Insulin Signaling—TSC2—vascular cancer	0.000262	0.00398	CbGpPWpGaD
Crizotinib—MAPK7—Insulin Signaling—TSC2—vascular cancer	0.000256	0.00389	CbGpPWpGaD
Crizotinib—RPS6KB1—IRS-mediated signalling—TSC2—vascular cancer	0.000256	0.00389	CbGpPWpGaD
Crizotinib—MAP3K2—BDNF signaling pathway—TSC2—vascular cancer	0.000254	0.00386	CbGpPWpGaD
Crizotinib—AURKA—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.000251	0.00381	CbGpPWpGaD
Crizotinib—RPS6KB1—IRS-related events—TSC2—vascular cancer	0.000249	0.00378	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—WWTR1—vascular cancer	0.000247	0.00376	CbGpPWpGaD
Crizotinib—RPS6KB1—IRS-related events triggered by IGF1R—TSC2—vascular cancer	0.000247	0.00375	CbGpPWpGaD
Crizotinib—RPS6KB1—Insulin receptor signalling cascade—TSC2—vascular cancer	0.00024	0.00365	CbGpPWpGaD
Crizotinib—RPS6KB1—IGF1R signaling cascade—TSC2—vascular cancer	0.00024	0.00365	CbGpPWpGaD
Crizotinib—EPHA2—Direct p53 effectors—TSC2—vascular cancer	0.000237	0.00361	CbGpPWpGaD
Crizotinib—MAP3K2—Insulin Signaling—TSC2—vascular cancer	0.000233	0.00355	CbGpPWpGaD
Crizotinib—MAP4K1—Insulin Signaling—TSC2—vascular cancer	0.000233	0.00355	CbGpPWpGaD
Crizotinib—NTRK1—PI3K/AKT activation—TSC2—vascular cancer	0.00023	0.00349	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—WWTR1—vascular cancer	0.000211	0.0032	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—WWTR1—vascular cancer	0.00021	0.0032	CbGpPWpGaD
Crizotinib—MAPK7—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.000209	0.00318	CbGpPWpGaD
Crizotinib—MAP3K3—Insulin Signaling—TSC2—vascular cancer	0.000201	0.00305	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling by Insulin receptor—TSC2—vascular cancer	0.000199	0.00303	CbGpPWpGaD
Crizotinib—TYK2—IRS-mediated signalling—TSC2—vascular cancer	0.000199	0.00303	CbGpPWpGaD
Crizotinib—TYK2—IRS-related events—TSC2—vascular cancer	0.000194	0.00295	CbGpPWpGaD
Crizotinib—TYK2—IRS-related events triggered by IGF1R—TSC2—vascular cancer	0.000192	0.00292	CbGpPWpGaD
Crizotinib—TYK2—Insulin receptor signalling cascade—TSC2—vascular cancer	0.000187	0.00284	CbGpPWpGaD
Crizotinib—TYK2—IGF1R signaling cascade—TSC2—vascular cancer	0.000187	0.00284	CbGpPWpGaD
Crizotinib—CDK7—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.000185	0.00281	CbGpPWpGaD
Crizotinib—PTK2B—BDNF signaling pathway—TSC2—vascular cancer	0.000181	0.00275	CbGpPWpGaD
Crizotinib—TXK—Immune System—CD34—vascular cancer	0.000179	0.00272	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—WWTR1—vascular cancer	0.000176	0.00268	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—WWTR1—vascular cancer	0.000176	0.00268	CbGpPWpGaD
Crizotinib—NTRK1—BDNF signaling pathway—TSC2—vascular cancer	0.000173	0.00263	CbGpPWpGaD
Crizotinib—RPS6KB1—BDNF signaling pathway—TSC2—vascular cancer	0.000168	0.00255	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—WWTR1—vascular cancer	0.000167	0.00254	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by NGF—TSC2—vascular cancer	0.000161	0.00245	CbGpPWpGaD
Crizotinib—TYK2—Signaling by Insulin receptor—TSC2—vascular cancer	0.000155	0.00236	CbGpPWpGaD
Crizotinib—RPS6KB1—Insulin Signaling—TSC2—vascular cancer	0.000154	0.00234	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—WWTR1—vascular cancer	0.000153	0.00232	CbGpPWpGaD
Crizotinib—JAK2—IRS-mediated signalling—TSC2—vascular cancer	0.000151	0.0023	CbGpPWpGaD
Crizotinib—JAK2—IRS-related events—TSC2—vascular cancer	0.000147	0.00223	CbGpPWpGaD
Crizotinib—JAK2—IRS-related events triggered by IGF1R—TSC2—vascular cancer	0.000146	0.00221	CbGpPWpGaD
Crizotinib—YES1—Signaling by SCF-KIT—TSC2—vascular cancer	0.000144	0.0022	CbGpPWpGaD
Crizotinib—JAK2—IGF1R signaling cascade—TSC2—vascular cancer	0.000142	0.00216	CbGpPWpGaD
Crizotinib—JAK2—Insulin receptor signalling cascade—TSC2—vascular cancer	0.000142	0.00216	CbGpPWpGaD
Crizotinib—BLK—B Cell Activation—TSC2—vascular cancer	0.000138	0.00211	CbGpPWpGaD
Crizotinib—LYN—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.000136	0.00207	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—CD34—vascular cancer	0.000136	0.00206	CbGpPWpGaD
Crizotinib—RIPK2—Adaptive Immune System—CD34—vascular cancer	0.000134	0.00204	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—WWTR1—vascular cancer	0.000133	0.00203	CbGpPWpGaD
Crizotinib—TXK—Innate Immune System—TSC2—vascular cancer	0.000133	0.00202	CbGpPWpGaD
Crizotinib—TYK2—Signaling by SCF-KIT—TSC2—vascular cancer	0.000133	0.00202	CbGpPWpGaD
Crizotinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—TSC2—vascular cancer	0.000131	0.00199	CbGpPWpGaD
Crizotinib—NTRK1—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	0.00013	0.00198	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—CD34—vascular cancer	0.000129	0.00196	CbGpPWpGaD
Crizotinib—YES1—Signaling by ERBB2—TSC2—vascular cancer	0.000129	0.00195	CbGpPWpGaD
Crizotinib—TYK2—Downstream signaling of activated FGFR—TSC2—vascular cancer	0.000127	0.00193	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—WWTR1—vascular cancer	0.000125	0.00191	CbGpPWpGaD
Crizotinib—TYK2—Signaling by ERBB4—TSC2—vascular cancer	0.000125	0.0019	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—CD34—vascular cancer	0.000123	0.00188	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—CD34—vascular cancer	0.000123	0.00188	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—WWTR1—vascular cancer	0.000121	0.00184	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways in Glioblastoma—TSC2—vascular cancer	0.000121	0.00183	CbGpPWpGaD
Crizotinib—TYK2—Downstream signal transduction—TSC2—vascular cancer	0.00012	0.00182	CbGpPWpGaD
Crizotinib—TYK2—Signaling by FGFR—TSC2—vascular cancer	0.000119	0.00181	CbGpPWpGaD
Crizotinib—TYK2—Signaling by ERBB2—TSC2—vascular cancer	0.000118	0.0018	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—WWTR1—vascular cancer	0.000118	0.0018	CbGpPWpGaD
Crizotinib—LCK—PI-3K cascade—TSC2—vascular cancer	0.000118	0.00179	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—HBA1—vascular cancer	0.000118	0.00179	CbGpPWpGaD
Crizotinib—TYK2—DAP12 signaling—TSC2—vascular cancer	0.000118	0.00179	CbGpPWpGaD
Crizotinib—JAK2—Signaling by Insulin receptor—TSC2—vascular cancer	0.000118	0.00179	CbGpPWpGaD
Crizotinib—CDK7—Disease—WWTR1—vascular cancer	0.000116	0.00177	CbGpPWpGaD
Crizotinib—LCK—PI3K/AKT activation—TSC2—vascular cancer	0.000115	0.00175	CbGpPWpGaD
Crizotinib—LCK—GAB1 signalosome—TSC2—vascular cancer	0.000114	0.00174	CbGpPWpGaD
Crizotinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—TSC2—vascular cancer	0.000112	0.0017	CbGpPWpGaD
Crizotinib—TYK2—DAP12 interactions—TSC2—vascular cancer	0.000111	0.00168	CbGpPWpGaD
Crizotinib—TYK2—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	0.000111	0.00168	CbGpPWpGaD
Crizotinib—TYK2—Signaling by FGFR in disease—TSC2—vascular cancer	0.000111	0.00168	CbGpPWpGaD
Crizotinib—TYK2—Signaling by EGFR—TSC2—vascular cancer	0.00011	0.00167	CbGpPWpGaD
Crizotinib—TYK2—Signaling by EGFR in Cancer—TSC2—vascular cancer	0.000109	0.00166	CbGpPWpGaD
Crizotinib—TYK2—Signaling by PDGF—TSC2—vascular cancer	0.000108	0.00165	CbGpPWpGaD
Crizotinib—LYN—Signaling by SCF-KIT—TSC2—vascular cancer	0.000108	0.00164	CbGpPWpGaD
Crizotinib—RIPK2—Signaling by NGF—TSC2—vascular cancer	0.000106	0.00161	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—CD34—vascular cancer	0.000104	0.00158	CbGpPWpGaD
Crizotinib—ABL1—Integrated Breast Cancer Pathway—TSC2—vascular cancer	0.000101	0.00154	CbGpPWpGaD
Crizotinib—SRC—GAB1 signalosome—TSC2—vascular cancer	0.000101	0.00154	CbGpPWpGaD
Crizotinib—IKBKE—Innate Immune System—TSC2—vascular cancer	0.000101	0.00153	CbGpPWpGaD
Crizotinib—TBK1—Immune System—CD34—vascular cancer	0.000101	0.00153	CbGpPWpGaD
Crizotinib—JAK2—Signaling by SCF-KIT—TSC2—vascular cancer	0.000101	0.00153	CbGpPWpGaD
Crizotinib—NTRK1—Signaling by NGF—TSC2—vascular cancer	9.99e-05	0.00152	CbGpPWpGaD
Crizotinib—JAK2—BDNF signaling pathway—TSC2—vascular cancer	9.91e-05	0.00151	CbGpPWpGaD
Crizotinib—TYK2—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	9.82e-05	0.00149	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—CD34—vascular cancer	9.67e-05	0.00147	CbGpPWpGaD
Crizotinib—JAK2—Downstream signaling of activated FGFR—TSC2—vascular cancer	9.64e-05	0.00147	CbGpPWpGaD
Crizotinib—JAK2—Signaling by ERBB4—TSC2—vascular cancer	9.49e-05	0.00144	CbGpPWpGaD
Crizotinib—MAPK7—Innate Immune System—TSC2—vascular cancer	9.18e-05	0.0014	CbGpPWpGaD
Crizotinib—LIMK1—Innate Immune System—TSC2—vascular cancer	9.18e-05	0.0014	CbGpPWpGaD
Crizotinib—JAK3—Immune System—CD34—vascular cancer	9.12e-05	0.00139	CbGpPWpGaD
Crizotinib—JAK2—Downstream signal transduction—TSC2—vascular cancer	9.06e-05	0.00138	CbGpPWpGaD
Crizotinib—JAK2—Signaling by FGFR—TSC2—vascular cancer	9.01e-05	0.00137	CbGpPWpGaD
Crizotinib—LYN—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	8.97e-05	0.00136	CbGpPWpGaD
Crizotinib—JAK2—Signaling by ERBB2—TSC2—vascular cancer	8.97e-05	0.00136	CbGpPWpGaD
Crizotinib—JAK2—DAP12 signaling—TSC2—vascular cancer	8.93e-05	0.00136	CbGpPWpGaD
Crizotinib—LCK—Signaling by SCF-KIT—TSC2—vascular cancer	8.82e-05	0.00134	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—WWTR1—vascular cancer	8.73e-05	0.00133	CbGpPWpGaD
Crizotinib—LCK—Downstream signaling of activated FGFR—TSC2—vascular cancer	8.44e-05	0.00128	CbGpPWpGaD
Crizotinib—JAK2—DAP12 interactions—TSC2—vascular cancer	8.4e-05	0.00128	CbGpPWpGaD
Crizotinib—JAK2—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	8.4e-05	0.00128	CbGpPWpGaD
Crizotinib—JAK2—Signaling by FGFR in disease—TSC2—vascular cancer	8.4e-05	0.00128	CbGpPWpGaD
Crizotinib—JAK2—Signaling by EGFR—TSC2—vascular cancer	8.32e-05	0.00127	CbGpPWpGaD
Crizotinib—LCK—Signaling by ERBB4—TSC2—vascular cancer	8.31e-05	0.00126	CbGpPWpGaD
Crizotinib—LYN—B Cell Activation—TSC2—vascular cancer	8.31e-05	0.00126	CbGpPWpGaD
Crizotinib—JAK2—Signaling by EGFR in Cancer—TSC2—vascular cancer	8.25e-05	0.00125	CbGpPWpGaD
Crizotinib—JAK2—Signaling by PDGF—TSC2—vascular cancer	8.21e-05	0.00125	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CD34—vascular cancer	8.13e-05	0.00124	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CD34—vascular cancer	8.01e-05	0.00122	CbGpPWpGaD
Crizotinib—LCK—Downstream signal transduction—TSC2—vascular cancer	7.94e-05	0.00121	CbGpPWpGaD
Crizotinib—TYK2—Disease—WWTR1—vascular cancer	7.91e-05	0.0012	CbGpPWpGaD
Crizotinib—LCK—Signaling by FGFR—TSC2—vascular cancer	7.9e-05	0.0012	CbGpPWpGaD
Crizotinib—LCK—Signaling by ERBB2—TSC2—vascular cancer	7.86e-05	0.00119	CbGpPWpGaD
Crizotinib—LCK—DAP12 signaling—TSC2—vascular cancer	7.82e-05	0.00119	CbGpPWpGaD
Crizotinib—BLK—Immune System—CD34—vascular cancer	7.82e-05	0.00119	CbGpPWpGaD
Crizotinib—SRC—Signaling by SCF-KIT—TSC2—vascular cancer	7.81e-05	0.00119	CbGpPWpGaD
Crizotinib—FGR—Immune System—CD34—vascular cancer	7.79e-05	0.00118	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—WWTR1—vascular cancer	7.78e-05	0.00118	CbGpPWpGaD
Crizotinib—IRAK1—Signaling by NGF—TSC2—vascular cancer	7.78e-05	0.00118	CbGpPWpGaD
Crizotinib—TXK—Immune System—TSC2—vascular cancer	7.75e-05	0.00118	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—CD34—vascular cancer	7.73e-05	0.00118	CbGpPWpGaD
Crizotinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—TSC2—vascular cancer	7.71e-05	0.00117	CbGpPWpGaD
Crizotinib—SRC—BDNF signaling pathway—TSC2—vascular cancer	7.68e-05	0.00117	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—WWTR1—vascular cancer	7.67e-05	0.00117	CbGpPWpGaD
Crizotinib—TYK2—Signaling by NGF—TSC2—vascular cancer	7.55e-05	0.00115	CbGpPWpGaD
Crizotinib—TBK1—Innate Immune System—TSC2—vascular cancer	7.5e-05	0.00114	CbGpPWpGaD
Crizotinib—JAK2—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	7.44e-05	0.00113	CbGpPWpGaD
Crizotinib—LCK—Fc epsilon receptor (FCERI) signaling—TSC2—vascular cancer	7.36e-05	0.00112	CbGpPWpGaD
Crizotinib—LCK—Signaling by FGFR in disease—TSC2—vascular cancer	7.36e-05	0.00112	CbGpPWpGaD
Crizotinib—LCK—DAP12 interactions—TSC2—vascular cancer	7.36e-05	0.00112	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—WWTR1—vascular cancer	7.34e-05	0.00112	CbGpPWpGaD
Crizotinib—LCK—Signaling by EGFR—TSC2—vascular cancer	7.29e-05	0.00111	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—TSC2—vascular cancer	7.23e-05	0.0011	CbGpPWpGaD
Crizotinib—LCK—Signaling by EGFR in Cancer—TSC2—vascular cancer	7.23e-05	0.0011	CbGpPWpGaD
Crizotinib—LCK—Signaling by PDGF—TSC2—vascular cancer	7.19e-05	0.00109	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—WWTR1—vascular cancer	7.11e-05	0.00108	CbGpPWpGaD
Crizotinib—SRC—Downstream signal transduction—TSC2—vascular cancer	7.02e-05	0.00107	CbGpPWpGaD
Crizotinib—SRC—Signaling by FGFR—TSC2—vascular cancer	6.99e-05	0.00106	CbGpPWpGaD
Crizotinib—SRC—Signaling by ERBB2—TSC2—vascular cancer	6.96e-05	0.00106	CbGpPWpGaD
Crizotinib—LCK—B Cell Activation—TSC2—vascular cancer	6.81e-05	0.00104	CbGpPWpGaD
Crizotinib—LCK—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	6.52e-05	0.000991	CbGpPWpGaD
Crizotinib—SRC—Signaling by FGFR in disease—TSC2—vascular cancer	6.51e-05	0.00099	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR—TSC2—vascular cancer	6.45e-05	0.000981	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR in Cancer—TSC2—vascular cancer	6.4e-05	0.000973	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD34—vascular cancer	6.38e-05	0.00097	CbGpPWpGaD
Crizotinib—SRC—Signaling by PDGF—TSC2—vascular cancer	6.37e-05	0.000968	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD34—vascular cancer	6.34e-05	0.000963	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD34—vascular cancer	6.29e-05	0.000956	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—TSC2—vascular cancer	6.15e-05	0.000935	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—WWTR1—vascular cancer	6.1e-05	0.000928	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—TSC2—vascular cancer	6.04e-05	0.000919	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—WWTR1—vascular cancer	6.02e-05	0.000915	CbGpPWpGaD
Crizotinib—JAK2—Disease—WWTR1—vascular cancer	6e-05	0.000912	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD34—vascular cancer	5.96e-05	0.000907	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—TSC2—vascular cancer	5.87e-05	0.000893	CbGpPWpGaD
Crizotinib—RIPK2—Adaptive Immune System—TSC2—vascular cancer	5.8e-05	0.000882	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—TSC2—vascular cancer	5.79e-05	0.000881	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD34—vascular cancer	5.79e-05	0.00088	CbGpPWpGaD
Crizotinib—SRC—NGF signalling via TRKA from the plasma membrane—TSC2—vascular cancer	5.77e-05	0.000877	CbGpPWpGaD
Crizotinib—JAK2—Signaling by NGF—TSC2—vascular cancer	5.72e-05	0.00087	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—WWTR1—vascular cancer	5.71e-05	0.000868	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD34—vascular cancer	5.61e-05	0.000853	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—TSC2—vascular cancer	5.58e-05	0.000849	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—WWTR1—vascular cancer	5.54e-05	0.000843	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—TSC2—vascular cancer	5.34e-05	0.000813	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—TSC2—vascular cancer	5.34e-05	0.000813	CbGpPWpGaD
Crizotinib—LCK—Disease—WWTR1—vascular cancer	5.25e-05	0.000799	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—TSC2—vascular cancer	5.15e-05	0.000783	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—TSC2—vascular cancer	5.15e-05	0.000783	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—TSC2—vascular cancer	5.01e-05	0.000762	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TSC2—vascular cancer	4.88e-05	0.000743	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—TSC2—vascular cancer	4.74e-05	0.000721	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD34—vascular cancer	4.69e-05	0.000713	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—TSC2—vascular cancer	4.68e-05	0.000711	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD34—vascular cancer	4.67e-05	0.00071	CbGpPWpGaD
Crizotinib—SRC—Disease—WWTR1—vascular cancer	4.65e-05	0.000707	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—TSC2—vascular cancer	4.49e-05	0.000683	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—WWTR1—vascular cancer	4.49e-05	0.000682	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TSC2—vascular cancer	4.47e-05	0.000679	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—TSC2—vascular cancer	4.44e-05	0.000674	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—TSC2—vascular cancer	4.44e-05	0.000674	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD34—vascular cancer	4.39e-05	0.000667	CbGpPWpGaD
Crizotinib—TBK1—Immune System—TSC2—vascular cancer	4.37e-05	0.000664	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—TSC2—vascular cancer	4.31e-05	0.000655	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—WWTR1—vascular cancer	4.2e-05	0.000639	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—TSC2—vascular cancer	4.19e-05	0.000637	CbGpPWpGaD
Crizotinib—JAK3—Immune System—TSC2—vascular cancer	3.95e-05	0.0006	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TSC2—vascular cancer	3.9e-05	0.000594	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD34—vascular cancer	3.84e-05	0.000584	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—WWTR1—vascular cancer	3.68e-05	0.000559	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TSC2—vascular cancer	3.53e-05	0.000537	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—TSC2—vascular cancer	3.52e-05	0.000535	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—TSC2—vascular cancer	3.49e-05	0.00053	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—TSC2—vascular cancer	3.47e-05	0.000528	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—TSC2—vascular cancer	3.47e-05	0.000527	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TSC2—vascular cancer	3.46e-05	0.000525	CbGpPWpGaD
Crizotinib—CDK7—Disease—TSC2—vascular cancer	3.41e-05	0.000518	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD34—vascular cancer	3.4e-05	0.000517	CbGpPWpGaD
Crizotinib—BLK—Immune System—TSC2—vascular cancer	3.39e-05	0.000515	CbGpPWpGaD
Crizotinib—FGR—Immune System—TSC2—vascular cancer	3.37e-05	0.000513	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—TSC2—vascular cancer	3.35e-05	0.000509	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—TSC2—vascular cancer	3.26e-05	0.000496	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—WWTR1—vascular cancer	3.26e-05	0.000495	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—WWTR1—vascular cancer	3.05e-05	0.000464	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—TSC2—vascular cancer	2.86e-05	0.000435	CbGpPWpGaD
Crizotinib—PTK2—Immune System—TSC2—vascular cancer	2.76e-05	0.00042	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—TSC2—vascular cancer	2.74e-05	0.000417	CbGpPWpGaD
Crizotinib—YES1—Immune System—TSC2—vascular cancer	2.72e-05	0.000414	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—TSC2—vascular cancer	2.58e-05	0.000393	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TSC2—vascular cancer	2.55e-05	0.000388	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—TSC2—vascular cancer	2.53e-05	0.000385	CbGpPWpGaD
Crizotinib—TYK2—Immune System—TSC2—vascular cancer	2.51e-05	0.000381	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—TSC2—vascular cancer	2.43e-05	0.000369	CbGpPWpGaD
Crizotinib—TYK2—Disease—TSC2—vascular cancer	2.32e-05	0.000352	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—WWTR1—vascular cancer	2.3e-05	0.00035	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TSC2—vascular cancer	2.28e-05	0.000346	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TSC2—vascular cancer	2.24e-05	0.000341	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TSC2—vascular cancer	2.15e-05	0.000326	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TSC2—vascular cancer	2.08e-05	0.000316	CbGpPWpGaD
Crizotinib—LYN—Immune System—TSC2—vascular cancer	2.03e-05	0.000309	CbGpPWpGaD
Crizotinib—ABL1—Immune System—TSC2—vascular cancer	2.02e-05	0.000307	CbGpPWpGaD
Crizotinib—JAK2—Immune System—TSC2—vascular cancer	1.9e-05	0.000289	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TSC2—vascular cancer	1.79e-05	0.000271	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TSC2—vascular cancer	1.76e-05	0.000268	CbGpPWpGaD
Crizotinib—JAK2—Disease—TSC2—vascular cancer	1.75e-05	0.000267	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—HBA1—vascular cancer	1.71e-05	0.00026	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TSC2—vascular cancer	1.67e-05	0.000254	CbGpPWpGaD
Crizotinib—LCK—Immune System—TSC2—vascular cancer	1.66e-05	0.000253	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TSC2—vascular cancer	1.62e-05	0.000247	CbGpPWpGaD
Crizotinib—LCK—Disease—TSC2—vascular cancer	1.54e-05	0.000234	CbGpPWpGaD
Crizotinib—SRC—Immune System—TSC2—vascular cancer	1.47e-05	0.000224	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—WWTR1—vascular cancer	1.42e-05	0.000216	CbGpPWpGaD
Crizotinib—SRC—Disease—TSC2—vascular cancer	1.36e-05	0.000207	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TSC2—vascular cancer	1.31e-05	0.0002	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HBA1—vascular cancer	1.29e-05	0.000196	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TSC2—vascular cancer	1.23e-05	0.000187	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TSC2—vascular cancer	1.08e-05	0.000164	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TSC2—vascular cancer	9.53e-06	0.000145	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HBA1—vascular cancer	7.95e-06	0.000121	CbGpPWpGaD
